Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor

Shouichi Ohga, Akihiko Nomura, Hidetoshi Takada, Naohiro Suga, Toshiro Hara

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Regular self-infusion of an activated prothrombin complex concentrate (APCC) has been successfully introduced to a 14-year-old boy with hemophilia A. The child was diagnosed as a neonate, and at age 7 years, developed a high titer (127 BU/mL) factor VIII inhibitor coincident with a protracted ankle joint bleeding. From age 7-10 years, he received on-demand therapy using a prothrombin complex concentrate (PCC), PROPLEX-ST. From age 10-14 years, he received prophylaxis with PROPLEX-ST, initiated after an intracranial hemorrhage and coincident anamnestic inhibitor response. Throughout 7-year period of PCC treatment, he experienced recurrent bleeding episodes. Self-prophylaxis with APCC, FEIBA VH [Anti-inhibitor Coagulant Complex] (50 U/kg/dose three times per week) using infusion pump was initiated at 14 years of age and has continued for 2 years. There were no bleeding, thrombotic events or other adverse events after initiation of this prophylaxis, and inhibitor levels decreased to 1 BU/mL. His quality of life was improved, particularly with respect to school. Our long observation proposes a well-disciplined home-based FEIBA prophylaxis in inhibitor-positive hemophiliacs.

Original languageEnglish
Pages (from-to)145-149
Number of pages5
JournalAmerican Journal of Hematology
Volume82
Issue number2
DOIs
Publication statusPublished - Feb 1 2007

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor'. Together they form a unique fingerprint.

  • Cite this